CxBladder test kits available on line in NZ at $368
Printable View
CxBladder test kits available on line in NZ at $368
DD speaking to sharesies today
https://www.youtube.com/watch?v=PDvlEGHr9BQ
Not in NZ. The US Market is where they get that and then some..
I'm a hospital clinical staff member & hope this answers part of your question.
I just checked our DHB guidelines and CxBladderTriage is firmly entrenched in the workup procedure for both patients currently in hospital, and those who are at home. I see patients referred for CxBladder during my routine work.
At my DHB, the CxBladder test is used as a screening test for patients with haematuria (blood in the urine) that isn't explained by a bladder infection. Some higher risk patients also have an ultrasound at this point. Our guidelines highlight that it picks up 97% of urological cancers, and will 'rule out' 99% of patients who don't have bladder cancer. If a positive result is reported, the patient is then referred to the urologist. This is when further specialist investigations such as imaging may be undertaken, to both finalise a diagnosis and decide upon a treatment plan.
(replying to psychic from 7/8/21)
Thanks Psychic.
The excellent negative predictive value and it’s apparent 100% ( though I am always wary of any thing said to be 100% in medicine) detection of nasty tumours will hugely reduce the uncertainty in managing haematuria in the primary care setting at least. If you receive a negative result then you can watch and repeat later knowing in the very small chance of a tumour being missed at least it won’t be at the nasty end of the spectrum. This will take pressure ( probably quite a lot ) off imaging and, Hallelujah for the patients, cut down cystoscopy numbers significantly with an attendant saving in resources. Win win win all around. Haematuria ( particularly microscopic) was often the source of significant clinical management anxiety for me in primary care and I believe my colleagues and this testing process will leave a clearer path in many cases which would otherwise have carried a significant burden of uncertainty for the clinician and patients as will as inconvenience and discomfort for the latter
Lescy and Retired Doc, thank you both for these excellent posts.
Thank you Psychic.You are welcome. I think it is important to refresh views as new information becomes available even if it only confirms previous positions. This most recent study is another plank in a very sound base. IMHO CxBladder will be a fundamental part of any haematuria work up algorithm.
Any idea why the take-up rate is so slow in USA? I would off thought even the most mercenary urologist in USA would have seen the merit of clipping the ticket during lock-down by getting "clients" to take the test, they must have had a database of suitable candidates to draw on.
Ethical urologists would have sent them to do the best by their patients.
What am I missing?
My 2c take is that CxBladder is a major disruptor and the AUA is likely a very conservative organisation. Also as you are likely aware the US health system bears a heavy litigation burden and there will be some anxiety re omitting an erstwhile gold standard procedure (cystoscopy) where you actually “have a look” and using a molecular test. What will likely weigh against persisting with cystoscopy is patient preference and the fact that there is a complication rate and morbidity with cystoscopy which although very low does raise the spectre of a lawyer asking in the situation of a cystoscopy gone wrong, why cystoscopy was done when a simple urine test would have sufficed.
I am not sure how the money flows in the US but cutting down on cystoscopies is going to decrease revenue for some urologists and hospitals/ clinics. Insurance companies should love CxB but again I donÂ’t know the details of the system.
I believe CxB is now popular in NZ urology practice and it wonÂ’t be far off penetrating primary care here albeit with some restrictions.
I feel confident that my modest PEB holding will grow but being largely ignorant of the economics of this I have no idea of by what factor the increasing numbers of tests will translate into profits. There will be others out there who may be able to comment on thatÂ…Â…Â…
Thank you Retired Doctor.
Yip, guidelines move soooooo slow, when I first looked at this guideline, cxbladder had half a page on information. 5 years on we have 7 pages of information. At least it allows coverage in certain cases.
https://www.google.com/url?sa=t&sour...UKgyehz5aAvlae
PACIFIC EDGE REPORTS CONTINUED GROWTH MOMENTUM INTO Q1 FY22
PACIFIC EDGE’S Q1 FY22 Update
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has reported a continuation of the positive growth momentum seen in the second half of the prior financial year, with sales of its Cxbladder tests continuing their strong growth.
The company, which is holding its Annual Meeting in Dunedin today, has delivered a record quarter in both test throughput and cash receipts for the three months from 1 April to 30 June 2021.
Laboratory throughput has risen consistently over the last five quarters
179% on the same time last year
109% increase on the preceding quarter (Q4 FY21)
Cash Receipts from Customers also continue to grow as reimbursement success and volumes grow.
242% on the same time last year
121% increase on the preceding quarter (Q4 FY21)
Growth Outlook
Pacific Edge has a positive growth outlook, with opportunities being addressed in each of its key markets. The priorities going forward are to firstly encourage commercial use of Cxbladder by large scale institutional healthcare organisations in each market; and secondly, to encourage customers to include multiple products from the Cxbladder suite of tests in their standard of care and mainstream commercial use.
The US remains the primary focus, with an annual addressable market of US$3.5 billion . With the Company’s recent commercial milestones achieved in reimbursement for tests, Pacific Edge has scaled up its sales team and resources in the US. An increasing number of commercial tests from the CMS, Kaiser Permanente and other scale payers such as United Healthcare are expected to underpin revenue and operating cashflow growth in FY22 and beyond. The company notes that the impact of the Covid-19 pandemic is still being felt, particularly restricted access to clinics and urologists for Pacific Edge’s sales team.
The focus in New Zealand is expanding the coverage by New Zealand’s public healthcare providers and continuing the evolution towards mainstream commercial use of more than one Cxbladder product. Australia and South East Asia are at an earlier stage in their commercial journey, with the goal being to transition the large scale public healthcare providers from clinical trials to a commercial customer model.
CEO David Darling said: “Our recent progress and commercial achievements over FY21 underpin our future growth. We are now seeing the commercial benefits of our efforts and the resources that have gone into the development and commercialisation of our Cxbladder technology, rolling into the company’s performance in the first quarter of FY22.”
ENDS
Great news for holders.
Laboratory throughput has risen consistently over the last five quarters
§ 179% on the same time last year
§ 109% increase on the preceding quarter (Q4 FY21)
Cash Receipts from Customers also continue to grow as reimbursement success and volumes grow.
§ 242% on the same time last year
§ 121% increase on the preceding quarter (Q4 FY21)
Easier to read the ann via the NZX website.
Specially good that cash receipts are well-up.
The good news journey continues.
We're not on a bullet train, but I think we're no longer on a roller coaster with PEB.
Wonder why there is still a relatively large sell volume sitting around 1.25. If only those sellers would just remove or increase their sell price then the share price could continue on its merry way. Seems this block there is prevent the natural progression of the SP rallying. Let the good news take course.
Take a break sellers and let the bull run :)
Amended notice
Not so well-up then ;). Cancel that reversing truck.